Relmada Therapeutics, Inc. RLMD Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s weighted average exercise price of outstanding options?
- Relmada Therapeutics, Inc. (RLMD) reported weighted average exercise price of outstanding options of $12.51 in Q1 2026.
- What is the long-term trend for Relmada Therapeutics, Inc.'s weighted average exercise price of outstanding options?
- Over 2 years (2022 to 2025), Relmada Therapeutics, Inc.'s weighted average exercise price of outstanding options has grown at a -14.3% compound annual growth rate (CAGR), from $17.02 to $12.51.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.